Why the study?
Does alprenolol reduce blood pressure in African hypertensive patients?
Does alprenolol reduce blood pressure in African hypertensive patients?
Alprenolol may be less effective at lowering blood pressure in African hypertensive patients compared to the typical response observed in Caucasians.
Alprenolol yields smaller BP reductions in African hypertensives than typical Caucasian responses; challenges extrapolation of beta-blocker efficacy across ethnic groups.
A placebo-controlled, double-blind clinical trial of alprenolol was carried out in 20 hypertensive Africans. The active drug and placebo were each administered for 8 weeks using a crossover design. Alprenolol was given in the form of a slow-release tablet preparation at a dosage of 200 mg twice daily. Four patients were withdrawn from the study either because of side-effects (2 patients) or non-compliance (2 patients). The mean reduction in blood pressure obtained in the 16 patients who completed the trial was less than that usually reported in Caucasians.
No takes yet. Share an insight, caveat, or question.
Salako et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: